Berlin - Delayed Quote EUR
MediPharm Labs Corp (MLZ.BE)
0.0538
+0.0032
+(6.32%)
At close: April 25 at 8:04:36 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
41,961
41,961
33,062
22,117
21,711
Cost of Revenue
29,156
29,156
27,207
24,031
36,957
Gross Profit
12,805
12,805
5,855
-1,914
-15,246
Operating Expense
23,373
23,373
23,602
26,870
27,763
Operating Income
-10,568
-10,568
-17,747
-28,784
-43,009
Net Non Operating Interest Income Expense
115
115
475
448
-10,281
Other Income Expense
-241
-241
3,913
-1,653
-1,398
Pretax Income
-10,694
-10,694
-13,359
-29,989
-54,688
Tax Provision
--
--
-276
-6
113
Net Income Common Stockholders
-10,694
-10,694
-13,083
-29,983
-54,801
Diluted NI Available to Com Stockholders
-10,694
-10,694
-13,083
-29,983
-54,801
Basic EPS
-0.03
--
-0.04
-0.11
-0.22
Diluted EPS
-0.03
--
-0.04
-0.11
-0.22
Basic Average Shares
407,993.3530
--
363,323.9520
276,861.1090
249,906.8040
Diluted Average Shares
407,993.3530
--
363,323.9520
276,861.1090
249,906.8040
Total Operating Income as Reported
-10,809
-10,809
-18,252
-29,533
-48,916
Rent Expense Supplemental
1,322
1,322
1,300
586
366
Total Expenses
52,529
52,529
50,809
50,901
64,720
Net Income from Continuing & Discontinued Operation
-10,694
-10,694
-13,083
-29,983
-54,801
Normalized Income
-10,453
-10,453
-16,915.1565
-28,330.3307
-53,773.4700
Interest Income
691
691
840
479
225
Interest Expense
576
576
365
31
10,506
Net Interest Income
115
115
475
448
-10,281
EBIT
-10,118
-10,118
-12,994
-29,958
-44,182
EBITDA
-7,518
-7,518
-10,478
-27,086
-38,549
Reconciled Cost of Revenue
26,987
26,987
25,144
21,990
32,738
Reconciled Depreciation
2,600
2,600
2,516
2,872
5,633
Net Income from Continuing Operation Net Minority Interest
-10,694
-10,694
-13,083
-29,983
-54,801
Total Unusual Items Excluding Goodwill
-241
-241
3,913
-1,653
-1,398
Total Unusual Items
-241
-241
3,913
-1,653
-1,398
Normalized EBITDA
-7,277
-7,277
-14,391
-25,433
-37,151
Tax Rate for Calcs
--
--
0
0
0.0003
Tax Effect of Unusual Items
--
--
80.8435
-0.3307
-370.4700
12/31/2021 - 3/5/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade